ASCO 2020: Conference Summary Online

affected by medical needs, patient tissue, payment environment and other factors, cancer is still the main investment direction of the pharmaceutical industryBecause tumor phenotypes are relatively simple (cell growth is out of control), and many non-specific factors can effectively inhibit tumor growth in in vitro or animal models, it is not easy to accurately determine which drugs are really promising before the clinicHypothesis a lot, each is at least effective in some models, but the clinical failure rate of cancer drugs is still relatively high, and the real improvement in standard therapies is even rarerTherefore, whether the early clinical of new mechanism drugs can show the potential of the future Lion King, especially unilateral activity, whether the mature drug phase III clinical can significantly surpass standard therapy, especially OS improvement are investors, doctors, patients are very concerned about the progresskiller PROTAC debuts
Arvinas' AR receptor PROTAC ARV-110 debuted as a key proof of concept for this new small molecule technologyThe ARV-110 is safe, with 2 psA in 15 people down by 50% and one with two AR variantsThe results are far from stunning, but without serious side effects, showing a certain effect is a valuable first stepCAR-T towards standardizationnow self-CAR-T many patients because of physical problems can not be used, can be used is not as easy as heterogeneous CAR-T use, quality stabilityALLO's allogeneic CAR-T drug ALLO-501 produced a 78% response rate in 12 patients with blood tumors, 3 of which had CRThe trial did not find serious side effects such as GvHD or patient deaths, an important advance in CAR-T's progress from the body to the allogeneic bodyimmunotherapy was followed by a combination ofRoche's TIGIT antibody tiragolumab, PD-L1 antibody atezolizumab in PD-L1-positive lung cancer patients with a response rate of 55%, more than 16% of atezolizumabThe median PFS is 5.4 and 3.6 months, respectively, showing some prospects, but whether it will be able to become the emperor of lung cancer K drug pull off the horse there are still many questionsGlaxo's ICOS receptor agonist GSK609 produced a 26% response rate in patients with head and neck cancer, showing some prospects MGNX's PD-L1/LAG-3 double anti-MGD013 single-sided response rate of 10-20% in LAG-3-positive solid tumor patients, but including some unverified responses Fc needs to be personalized
MGNX's Fc modified HER2 antibody margetuximab and PD-L1/LAG-3 double anti-MGD013 produced a 43% response rate in PATIENTs with HER2 solid tumor, but this appears to be mainly due to margetuximab activity due to lower expression of PD-L1 or LAG-3 in patients with response patients New technology has led her2 drugs to begin expanding beyond breast cancer ADC Star Tactics First three-in-one Enhertu had a high response rate in a variety of HER2 solid tumors (CRC: 45%; stomach cancer: 51%; lung cancer: 62%), TROP2 ADC drugs produced a 22% response rate in lung cancer and a 38% response rate at the highest tolerable dose The B7H3 antibody ADC drug MGC018 caused 5 PSAs in five patients with advanced prostate cancer to drop by more than 50%, but the response rate was 0% KRAS really going to be shorted? Amgen's KRAS inhibitor AMG510 was clinically weak in a phase 1 called CodeBreak100, with only three partial responses in 22 patients with lung cancer and solid tumors other than CRC The partial response rate of the highest dose in 42 CRC patients was 12% and the response time was 4.3 months lung cancer phase III extended OS ShiGuibao's Nipi/chemotherapy combination although reducing the risk of death, the number of chemotherapy is limited, but now not only is it a little too late, but also an additional CTLA4 antibody combination is not as long as the survival of k drug/chemotherapy combination, the impact is limited today to see these i think more important progress, I hope there are other surprises will be announced Tumors are a group of highly complex diseases, and the distinction between fatal late tumors and relatively harmless early tumors and even normal tissueates at the molecular level is not well understood Today's preclinical optimization model is also mainly applicable to the killing of crude anti-cancer drugs, which makes the clinical treatment window a huge obstacle, the real disruptive innovation is still slow to emerge author: MedSci Source: MedSci Original